Annual Current Liabilities
$200.75 M
+$22.84 M+12.84%
December 31, 2024
Summary
- As of February 26, 2025, TVTX annual total current liabilities is $200.75 million, with the most recent change of +$22.84 million (+12.84%) on December 31, 2024.
- During the last 3 years, TVTX annual current liabilities has risen by +$76.66 million (+61.78%).
- TVTX annual current liabilities is now at all-time high.
Performance
TVTX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$200.75 M
+$10.71 M+5.64%
December 1, 2024
Summary
- As of February 26, 2025, TVTX quarterly total current liabilities is $200.75 million, with the most recent change of +$10.71 million (+5.64%) on December 1, 2024.
- Over the past year, TVTX quarterly current liabilities has increased by +$22.84 million (+12.84%).
- TVTX quarterly current liabilities is now at all-time high.
Performance
TVTX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
TVTX Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.8% | +12.8% |
| 3 y3 years | +61.8% | +12.8% |
| 5 y5 years | +110.3% | +12.8% |
TVTX Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.8% | at high | +68.0% |
| 5 y | 5-year | at high | +116.7% | at high | +194.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Travere Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $200.75 M(+12.8%) | - |
| Dec 2024 | - | $200.75 M(+5.6%) |
| Sep 2024 | - | $190.04 M(+56.7%) |
| Jun 2024 | - | $121.27 M(-30.0%) |
| Mar 2024 | - | $173.23 M(-2.6%) |
| Dec 2023 | $177.91 M(+25.1%) | $177.91 M(+27.6%) |
| Sep 2023 | - | $139.43 M(+2.7%) |
| Jun 2023 | - | $135.71 M(+3.9%) |
| Mar 2023 | - | $130.65 M(-8.1%) |
| Dec 2022 | $142.16 M(+14.6%) | $142.16 M(+8.5%) |
| Sep 2022 | - | $131.03 M(+5.3%) |
| Jun 2022 | - | $124.49 M(+4.2%) |
| Mar 2022 | - | $119.47 M(-3.7%) |
| Dec 2021 | $124.09 M(+33.9%) | $124.09 M(+9.7%) |
| Sep 2021 | - | $113.16 M(+16.7%) |
| Jun 2021 | - | $96.98 M(+14.1%) |
| Mar 2021 | - | $85.01 M(-8.3%) |
| Dec 2020 | $92.66 M(-2.9%) | $92.66 M(+22.8%) |
| Sep 2020 | - | $75.43 M(+7.9%) |
| Jun 2020 | - | $69.93 M(+2.7%) |
| Mar 2020 | - | $68.09 M(-28.7%) |
| Dec 2019 | $95.45 M(-8.8%) | $95.45 M(+8.4%) |
| Sep 2019 | - | $88.02 M(-2.8%) |
| Jun 2019 | - | $90.59 M(-13.0%) |
| Mar 2019 | - | $104.08 M(-0.5%) |
| Dec 2018 | $104.62 M(+22.1%) | $104.62 M(+4.8%) |
| Sep 2018 | - | $99.87 M(-3.5%) |
| Jun 2018 | - | $103.50 M(+83.1%) |
| Mar 2018 | - | $56.52 M(-34.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $85.67 M(+2.9%) | $85.67 M(+2.1%) |
| Sep 2017 | - | $83.90 M(+5.4%) |
| Jun 2017 | - | $79.63 M(+4.0%) |
| Mar 2017 | - | $76.56 M(-8.1%) |
| Dec 2016 | $83.26 M(-4.3%) | $83.26 M(-3.2%) |
| Sep 2016 | - | $85.99 M(+7.4%) |
| Jun 2016 | - | $80.07 M(+20.2%) |
| Mar 2016 | - | $66.62 M(-23.4%) |
| Dec 2015 | $86.98 M(-19.1%) | $86.98 M(-14.7%) |
| Sep 2015 | - | $101.95 M(-40.9%) |
| Jun 2015 | - | $172.38 M(+68.7%) |
| Mar 2015 | - | $102.17 M(-5.0%) |
| Dec 2014 | $107.54 M(+194.1%) | $107.54 M(+118.9%) |
| Sep 2014 | - | $49.13 M(+2.4%) |
| Jun 2014 | - | $47.98 M(-57.7%) |
| Mar 2014 | - | $113.45 M(+210.3%) |
| Dec 2013 | $36.56 M(+530.5%) | $36.56 M(+34.6%) |
| Sep 2013 | - | $27.17 M(+144.1%) |
| Jun 2013 | - | $11.13 M(+816.0%) |
| Mar 2013 | - | $1.22 M(+1668.6%) |
| Dec 2012 | $5.80 M(+8555.4%) | - |
| Nov 2012 | - | $68.70 K(+1.0%) |
| Aug 2012 | - | $68.00 K(+0.7%) |
| May 2012 | - | $67.50 K(+0.7%) |
| Feb 2012 | - | $67.00 K(+2.0%) |
| Feb 2012 | $67.00 K(+4.4%) | - |
| Nov 2011 | - | $65.70 K(+63.4%) |
| Aug 2011 | - | $40.20 K(-37.4%) |
| Feb 2011 | $64.20 K | $64.20 K |
FAQ
- What is Travere Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Travere Therapeutics?
- What is Travere Therapeutics annual current liabilities year-on-year change?
- What is Travere Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Travere Therapeutics?
- What is Travere Therapeutics quarterly current liabilities year-on-year change?
What is Travere Therapeutics annual total current liabilities?
The current annual current liabilities of TVTX is $200.75 M
What is the all time high annual current liabilities for Travere Therapeutics?
Travere Therapeutics all-time high annual total current liabilities is $200.75 M
What is Travere Therapeutics annual current liabilities year-on-year change?
Over the past year, TVTX annual total current liabilities has changed by +$22.84 M (+12.84%)
What is Travere Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of TVTX is $200.75 M
What is the all time high quarterly current liabilities for Travere Therapeutics?
Travere Therapeutics all-time high quarterly total current liabilities is $200.75 M
What is Travere Therapeutics quarterly current liabilities year-on-year change?
Over the past year, TVTX quarterly total current liabilities has changed by +$22.84 M (+12.84%)